Recent Research Analysts’ Ratings Updates for Entera Bio (ENTX)

Several analysts have recently updated their ratings and price targets for Entera Bio (NASDAQ: ENTX):

• 9/24/2026 – Entera Bio is now covered by Guggenheim. They set a “buy” rating and a $11.00 price target on the stock.
• 9/24/2026 – Entera Bio was upgraded by Guggenheim to “strong-buy”.
• 9/23/2026 – Entera Bio is now covered by Lifesci Capital. They set an “outperform” rating and a $10.00 price target on the stock.
• 9/22/2026 – Entera Bio is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
• 9/18/2026 – Entera Bio was given a new $9.00 price target by UBS Group AG.
• 9/18/2026 – Entera Bio is now covered by Leerink Partners. They set an “outperform” rating and a $9.00 price target on the stock.

Entera Bio Ltd. is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company’s proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.

Entera Bio’s pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism.